- Home
- TDS vs HAE Comparison
TDS vs HAE Comparison
Compare TDS & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDS
- HAE
- Stock Information
- Founded
- TDS 1968
- HAE 1971
- Country
- TDS United States
- HAE United States
- Employees
- TDS N/A
- HAE N/A
- Industry
- TDS Telecommunications Equipment
- HAE Medical/Dental Instruments
- Sector
- TDS Telecommunications
- HAE Health Care
- Exchange
- TDS Nasdaq
- HAE Nasdaq
- Market Cap
- TDS 3.9B
- HAE 3.3B
- IPO Year
- TDS N/A
- HAE 1991
- Fundamental
- Price
- TDS $33.21
- HAE $71.13
- Analyst Decision
- TDS Buy
- HAE Strong Buy
- Analyst Count
- TDS 2
- HAE 9
- Target Price
- TDS $50.00
- HAE $99.78
- AVG Volume (30 Days)
- TDS 742.4K
- HAE 505.1K
- Earning Date
- TDS 08-01-2025
- HAE 08-07-2025
- Dividend Yield
- TDS 0.48%
- HAE N/A
- EPS Growth
- TDS N/A
- HAE 44.54
- EPS
- TDS N/A
- HAE 3.31
- Revenue
- TDS $4,856,000,000.00
- HAE $1,360,824,000.00
- Revenue This Year
- TDS N/A
- HAE N/A
- Revenue Next Year
- TDS $0.40
- HAE $7.18
- P/E Ratio
- TDS N/A
- HAE $21.49
- Revenue Growth
- TDS N/A
- HAE 3.96
- 52 Week Low
- TDS $17.90
- HAE $55.30
- 52 Week High
- TDS $41.21
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- TDS 42.77
- HAE 60.48
- Support Level
- TDS $33.19
- HAE $68.62
- Resistance Level
- TDS $33.89
- HAE $73.78
- Average True Range (ATR)
- TDS 0.92
- HAE 1.53
- MACD
- TDS -0.11
- HAE -0.20
- Stochastic Oscillator
- TDS 2.91
- HAE 60.51
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.